Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group.

Next Previous
Trial Profile

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Cilengitide (Primary) ; Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Therapeutic Use
  • Acronyms HGG-Cil-Metro; HIT-HGG-CilMetro

    • Most Recent Events

    • 13 Jun 2014 European Clinical Trials Database record mentions trial status as ongoing.
    • 24 Apr 2014 Status changed from recruiting to discontinued, as per ClinicalTrials.gov record.
    • 11 Dec 2013 New source identified and integrated (German Clinical Trials Register; DRKS00005395).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top